Abdominal Binders to Minimize Enteral Nutrition Disruptions for Preterm Infants On Non-Invasive Respiratory Support
NCT ID: NCT07219784
Last Updated: 2025-10-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ENROLLING_BY_INVITATION
Clinical Phase
NA
Total Enrollment
120 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-07-30
Study Completion Date
2028-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this study is to learn if a foam belly strap, called "NeoBellyBand," can help with belly bloating, pauses in feedings, feeding success, and earlier discharge home for preterm infants who are requiring pressurized breathing support. Infants whose parents/ caregivers have consented to the study will be randomly chosen with a 50/50 chance of treatment with the NeoBellyBand or receiving standard NICU care. The main question it seeks to answer is if there are less interruptions to the feeding protocol for infants who have a NeoBellyBand placed on them compared with infants who do not. Infants on the treatment arm will have their bellies measured by trained personnel and have bands placed on them, which will be worn for most of the day while on breathing support with pressure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Baby ABS (Abdominal Binder Study)
NCT07049900
Premature
Premature Lungs
Ventilator Lung; Newborn
+1 more
RECRUITING
NA
Work of Breathing During Non-invasive Ventilation in Premature Neonates
NCT02788110
Respiratory Distress Syndrome, Newborn
Bronchopulmonary Dysplasia
COMPLETED
NA
Randomized Control Trial: Synchronized Non-invasive Positive Pressure Ventilation Versus Non Synchronized Non Invasive Positive Pressure Ventilation in Extremely Low Birth Weight Infants
NCT03613987
BPD - Bronchopulmonary Dysplasia
COMPLETED
NA
Nasal Noninvasive NAVA in the Very Low Birth Weight Infant
NCT01785563
Inadequate; Pulmonary Ventilation, Newborn
Infant, Very Low Birth Weight
COMPLETED
NA
Predicting the Need for Prolonged Respiratory Support in Neonates Delivered in a Lower-Level NICU Setting
NCT07344714
Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome in Premature Infant
Transient Tachypnea of the Newborn
+5 more
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background Preterm neonates who require respiratory support benefit from the use of non-invasive respiratory support over invasive mechanical ventilation to decrease rates of chronic lung disease \[1\]. Non-invasive support typically involves positive end-expiratory pressure which allows for distending pressures to keep the alveoli of the lungs open \[1\]. In our institution, this typically includes continuous positive airway pressure (CPAP) or non-invasive mechanical ventilation (NIMV). Mechanistically, due to the positioning of the trachea adjacent to the esophagus, the provision of pressure support for the lungs often results in additional air and pressure being supplied to the enteric tract. This can result in what is called "CPAP belly" \[2\]. Although CPAP belly was initially described as a benign gaseous distension, emerging evidence shows it has negative impacts on the functionality of the enteric tract, including delaying gastric emptying time \[2,3\]. A recent study characterizing CPAP belly has shown that it can lead to longer time to full enteral feeds, disruptions to feeding practices, and additional abdominal radiography \[4\].
Several strategies have been tried to decrease feeding intolerance in infants with abdominal distension, including early enteral feeds, which is our current practice, abdominal massages, and probiotic therapy \[5,6\]. Recently, a novel idea was proposed to combat the progression of CPAP belly: abdominal binding to support the abdominal wall musculature \[7\]. It was initially reported as a case study of two infants with significant abdominal distension while on respiratory support who had improvements in their distension back to expected range within one week of therapy initiation and without any reported adverse effects \[7\]. The author of this article has created a product, the NeoBellyBand for sale by the DandleLION Medical company, for use in her own institution. It is now in use in several institutions, given its minimal risk to patients and the potential benefits, as the new standard of care. In speaking with the developer of this product, we understand that there are also ongoing pre-and post-intervention studies looking at its impact on decreasing rates of chronic lung disease or length of stay in the NICU.
There is little published evidence for or against the use of abdominal binding in this population and there are no current studies that the research team is aware of looking at its impact on feeding practices in the NICU. Prior to the use of abdominal binding, we would like to study its safety and efficacy for the neonatal population. We hypothesize that the use of abdominal binders will lead to a decrease in feeding interruption events as well as a decrease in adverse feeding and respiratory outcomes for preterm neonates on non-invasive respiratory support.
The specific aims of this study are to:
1. Evaluate the impact of abdominal binders on decreasing interruptions to our unit feeding protocol due to feeding intolerance symptoms, such as increased abdominal distension or high-volume gastric residuals, compared with our current standard of care.
2. Analyze the effect of abdominal binding on time to major neonatal milestones, including discontinuation of respiratory support, discontinuation of parenteral nutrition, full oral feeds, discontinuation of therapies to promote regular stooling (such as glycerin suppositories or prune juice), and discharge from hospital.
3. Determine how the use of abdominal binders changes respiratory management (such as increasing respiratory pressures for worsening distension) and respiratory outcomes (such as chronic lung disease).
4. Evaluate the safety of abdominal binders by tracking possible adverse effects, including temperature regulation concerns, skin integrity concerns, and incidence and complications associated with umbilical or inguinal hernias.
B. STUDY DESIGN We propose a randomized controlled trial of hospitalized preterm neonates born less than 32 weeks and 0 days gestational age (GA) on non-invasive respiratory support to evaluate respiratory and enteral nutrition outcomes of infants using abdominal binders compared with infants who are not using them.
Primary outcome Days with interruptions to the feeding protocol, defined as interruptions to feeds or advances per our unit protocol for the infant's GA and birth weight (BW), due to feeding intolerance, defined as abdominal distension, increase in abdominal girth, abnormal stooling pattern, abdominal tenderness, increase in gastric residuals, emesis, and feeding-related cardiorespiratory events.
Secondary outcomes
* Age at which infant first achieved 120 mL/kg/day of enteral feeds, which is when IV fluids are typically discontinued in our unit
* Length of hospital admission and post-menstrual age (PMA) at discharge
* Number of abdominal radiographs obtained for abdominal concerns, as noted on the indication for the image or otherwise noted in the chart
* Rates of chronic lung disease (CLD), defined as oxygen requirement at 36 weeks PMA
* PMA when successfully off all respiratory support
* Rates of abnormal abdominal circumference (AC): head circumference (HC), namely AC:HC, defined as AC:HC \>95th %-ile for GA and PMA
* PMA at which infant achieves full oral feeds
Inclusion criteria for infants Born at \<32w0d GA Chronologic age \>7 days, treatment or control protocol started by 21 days of life On non-invasive positive pressure respiratory support (NIMV or CPAP), either as primary support or after extubation from invasive mechanical ventilation Has received 80 mL/kg/day of feeds at least once
Exclusion criteria for infants Skin integrity concerns Known abdominal or respiratory anomalies Umbilical lines in place Transferred to AMC NICU after 7 days of life Known genetic or major anatomic anomalies
Study Methodology Preterm infants who meet inclusion criteria will be identified upon admission to the AMC B4 NICU by the study team. They will be enrolled within the first 2-3 weeks of life by one of the physician study team members after obtaining written consent from the legal guardians.
There is no current method of tracking interruptions to feeds or disruptions to feed advancement. The study team did a preliminary analysis of infants born at \<32w0d who were discharged between September 2024 - January 2025. We found the mean number of feeding interruption days to be 1.9 and the standard deviation to be 2.7 for the duration of their hospital admission, using documentation in daily progress notes and nursing notes. Of note, one outlier infant with 69 feeding interruption days was excluded from analysis. However, we do not believe that all feeding interruption days are being captured given our understanding of the current arrangement for documentation. Therefore, we estimate that infants may have a mean of \~3 feeding interruptions during their hospital course. A power analysis was performed to detect a decrease in feeding interruption days with a mean of 3 days per infant (and a presumed standard deviation of 2.7) to a mean of 1 day per infant with 80% power and an alpha of 0.05. An adequate sample size would be 74 infants, 37 in each group (case and control), who complete the study. Given that we are allowing families the ability to withdraw from the study at any point in time, we will aim to enroll \~100-120 infants to ensure that at least 74 infants complete the study.
This study is expected to be completed within the next three years, or once 120 patients have been enrolled in and have completed the study, whichever is sooner. We currently have \~120 annual admissions of infants at this gestational age to the NICU. Assuming 25% declines enrollment and a smaller percentage do not meet the inclusion criteria, we would still have adequate numbers to complete this study within this time frame.
The infants will be participating in the study during their admission in the NICU, the duration of which ranges anywhere from 2 weeks to 4-6 months.
Study Design Randomization will occur using a block method within two separate strata, infants ≤28 weeks GA and infants between \>28 weeks to 32 weeks and 0 days. We will use block assignments of 8 infants, indicating that for each group of 8 infants enrolled, 4 will be assigned to the control group and 4 will be assigned to the treatment group. Unfortunately, we are unable to use blinding due to the treatment being a physically apparent intervention and the control being no intervention (which is our standard of care currently). The study team would ensure that infants allocated to the treatment group would receive the treatment starting between 8-21 days of age and once the infant has received at least one feed of 80 mL/kg/day, depending on the infant's skin maturity, as determined by the study team and in conjunction with the treating medical team. Infants who are intubated in the first week of life would qualify if they can be safely extubated within 2-3 weeks of life. Band placement would be started when they are extubated and on non-invasive support.
Device The device used in the treatment arm of this study will be the DandleLION NeoBellyBand. The NeoBellyBand is a Class 1 exempt abdominal binder which is included in DandleLION's Quality System and FDA registration. It is listed as a Medical Therapeutic Binder under product group MDR on Tarry Medical Products FDA establishment listing and does not require 510K clearance. (See: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm?lid=872457\&lpcd=MDR) Per the manufacturer, it is made of a medical-grade blend of fabric and foam that has been used safely on premature skin and has a soft foam inlay that is lightweight, breathable and moisture-wicking.
Treatment Protocol The band is intended to be in place at all times outside of cares times, skin-to-skin kangaroo care with the family, baths, and any procedures involving the abdomen. Once the bands have been placed on, they will stay in place while the infant is on non-invasive or invasive pressure support (CPAP, NIMV, or MV) and will be weaned off once the patient has been stable on high flow nasal cannula (HFNC) for two days. This means that for patients who have been exposed to non-invasive pressure ventilation and require re-intubation, the bands will also be worn during the time they remain re-intubated. The weaning will include three days of a schedule of 6 hour stretches with the band on and 6 hour stretches without the bands. If the patient requires pressure support again after the bands have been weaned off, the bands will be placed back on until they're weaned off pressure support again and weaned in the same way as above.
Control Protocol Infants will receive the standard of care for the NICU, except for additional data collection, which will include data on feeding interruptions and abdominal circumference measurements.
Data Collection from Chart The information that will be collected from the medical chart is information that is currently collected for patient care. The exceptions to this are the paper chart that tracks feeding disruptions and the nursing flow-sheet that tracks the times that the band is on or off, comments for when the band is off, and the abdominal circumference weekly. Data collected will include demographic information such as name, MRN, date of birth, sex, race and ethnicity, gestational age at birth and birth weight. It will include process measures, such as length of time the bands remained on the infant, documentation of abdominal circumference, abdominal circumference to head circumference measurement ratios, number of radiographs obtained for feeding intolerance, and glycerin use. It will include outcome measures, such as number of feeding interruption days, time to goal enteral feeds, time to all oral feeds, rates of chronic lung disease, necrotizing enterocolitis, spontaneous intestinal perforations, hernias and rates of incarcerated hernias, length of stay, and post-menstrual age at discharge.
Data Protection The study team members will collect retrospective data from their medical records securely, either while at the hospital, or through the secure Citrix system. The data will then be stored in a secure database, the RedCap database, for further analysis. The data contained within the RedCap database will be password-protected. Although the data collected will include protected health information and identifiable health information, all data will be de-identified prior to publication. Once the research study has been published, all identifiable data will be destroyed. De-identified data will be preserved as many journals now require a data availability statement.
Data Analysis For the primary outcome, the mean, standard deviation, standard error of the mean, and 95% confidence intervals will be calculated. The means will be compared between the cases and controls using a two-tailed t-test. If the primary outcome is noted to have a non-normal distribution, medians and interquartile ranges will be calculated and non-parametric Mann Whitney analyses will be conducted. For infants who do not withdraw from the study, an intent-to-treat analysis will be conducted. For secondary outcomes which have a continuous variable, the same statistical analyses will be used as the primary outcome. For secondary outcomes with a categorical variable, we will use proportions as well as chi-square tests. The statistical analyses will be conducted on the SPSS software and reviewed by a statistician.
Risk Monitoring Although we anticipate minimal risk to infants based on prior published data available about the NeoBellyBand, we will be tracking adverse events weekly. Rates of adverse events between the treatment and control arm will be analyzed after enrollment of the first 25 infants and will include documented pressure injuries and over-heating requiring removal of the band for \>6 hours. Although we do not anticipate any internal abdominal pathology to be a result of the placement of the bands, we will also be tracking rates of necrotizing enterocolitis, intestinal perforation, surgical abdomen, and incarcerated or strangulated hernias. Once the initial 25 patients have been enrolled (ideally about 11-14 from control group and treatment group), we will not start research interventions for new patients. We would continue to recruit more patients but will not carry out the research intervention until safety monitoring has been completed. The risk monitoring data will be reviewed by the research team, but also independently reviewed by a non-conflicted neonatologist at an outside institution.
Several strategies have been tried to decrease feeding intolerance in infants with abdominal distension, including early enteral feeds, which is our current practice, abdominal massages, and probiotic therapy \[5,6\]. Recently, a novel idea was proposed to combat the progression of CPAP belly: abdominal binding to support the abdominal wall musculature \[7\]. It was initially reported as a case study of two infants with significant abdominal distension while on respiratory support who had improvements in their distension back to expected range within one week of therapy initiation and without any reported adverse effects \[7\]. The author of this article has created a product, the NeoBellyBand for sale by the DandleLION Medical company, for use in her own institution. It is now in use in several institutions, given its minimal risk to patients and the potential benefits, as the new standard of care. In speaking with the developer of this product, we understand that there are also ongoing pre-and post-intervention studies looking at its impact on decreasing rates of chronic lung disease or length of stay in the NICU.
There is little published evidence for or against the use of abdominal binding in this population and there are no current studies that the research team is aware of looking at its impact on feeding practices in the NICU. Prior to the use of abdominal binding, we would like to study its safety and efficacy for the neonatal population. We hypothesize that the use of abdominal binders will lead to a decrease in feeding interruption events as well as a decrease in adverse feeding and respiratory outcomes for preterm neonates on non-invasive respiratory support.
The specific aims of this study are to:
1. Evaluate the impact of abdominal binders on decreasing interruptions to our unit feeding protocol due to feeding intolerance symptoms, such as increased abdominal distension or high-volume gastric residuals, compared with our current standard of care.
2. Analyze the effect of abdominal binding on time to major neonatal milestones, including discontinuation of respiratory support, discontinuation of parenteral nutrition, full oral feeds, discontinuation of therapies to promote regular stooling (such as glycerin suppositories or prune juice), and discharge from hospital.
3. Determine how the use of abdominal binders changes respiratory management (such as increasing respiratory pressures for worsening distension) and respiratory outcomes (such as chronic lung disease).
4. Evaluate the safety of abdominal binders by tracking possible adverse effects, including temperature regulation concerns, skin integrity concerns, and incidence and complications associated with umbilical or inguinal hernias.
B. STUDY DESIGN We propose a randomized controlled trial of hospitalized preterm neonates born less than 32 weeks and 0 days gestational age (GA) on non-invasive respiratory support to evaluate respiratory and enteral nutrition outcomes of infants using abdominal binders compared with infants who are not using them.
Primary outcome Days with interruptions to the feeding protocol, defined as interruptions to feeds or advances per our unit protocol for the infant's GA and birth weight (BW), due to feeding intolerance, defined as abdominal distension, increase in abdominal girth, abnormal stooling pattern, abdominal tenderness, increase in gastric residuals, emesis, and feeding-related cardiorespiratory events.
Secondary outcomes
* Age at which infant first achieved 120 mL/kg/day of enteral feeds, which is when IV fluids are typically discontinued in our unit
* Length of hospital admission and post-menstrual age (PMA) at discharge
* Number of abdominal radiographs obtained for abdominal concerns, as noted on the indication for the image or otherwise noted in the chart
* Rates of chronic lung disease (CLD), defined as oxygen requirement at 36 weeks PMA
* PMA when successfully off all respiratory support
* Rates of abnormal abdominal circumference (AC): head circumference (HC), namely AC:HC, defined as AC:HC \>95th %-ile for GA and PMA
* PMA at which infant achieves full oral feeds
Inclusion criteria for infants Born at \<32w0d GA Chronologic age \>7 days, treatment or control protocol started by 21 days of life On non-invasive positive pressure respiratory support (NIMV or CPAP), either as primary support or after extubation from invasive mechanical ventilation Has received 80 mL/kg/day of feeds at least once
Exclusion criteria for infants Skin integrity concerns Known abdominal or respiratory anomalies Umbilical lines in place Transferred to AMC NICU after 7 days of life Known genetic or major anatomic anomalies
Study Methodology Preterm infants who meet inclusion criteria will be identified upon admission to the AMC B4 NICU by the study team. They will be enrolled within the first 2-3 weeks of life by one of the physician study team members after obtaining written consent from the legal guardians.
There is no current method of tracking interruptions to feeds or disruptions to feed advancement. The study team did a preliminary analysis of infants born at \<32w0d who were discharged between September 2024 - January 2025. We found the mean number of feeding interruption days to be 1.9 and the standard deviation to be 2.7 for the duration of their hospital admission, using documentation in daily progress notes and nursing notes. Of note, one outlier infant with 69 feeding interruption days was excluded from analysis. However, we do not believe that all feeding interruption days are being captured given our understanding of the current arrangement for documentation. Therefore, we estimate that infants may have a mean of \~3 feeding interruptions during their hospital course. A power analysis was performed to detect a decrease in feeding interruption days with a mean of 3 days per infant (and a presumed standard deviation of 2.7) to a mean of 1 day per infant with 80% power and an alpha of 0.05. An adequate sample size would be 74 infants, 37 in each group (case and control), who complete the study. Given that we are allowing families the ability to withdraw from the study at any point in time, we will aim to enroll \~100-120 infants to ensure that at least 74 infants complete the study.
This study is expected to be completed within the next three years, or once 120 patients have been enrolled in and have completed the study, whichever is sooner. We currently have \~120 annual admissions of infants at this gestational age to the NICU. Assuming 25% declines enrollment and a smaller percentage do not meet the inclusion criteria, we would still have adequate numbers to complete this study within this time frame.
The infants will be participating in the study during their admission in the NICU, the duration of which ranges anywhere from 2 weeks to 4-6 months.
Study Design Randomization will occur using a block method within two separate strata, infants ≤28 weeks GA and infants between \>28 weeks to 32 weeks and 0 days. We will use block assignments of 8 infants, indicating that for each group of 8 infants enrolled, 4 will be assigned to the control group and 4 will be assigned to the treatment group. Unfortunately, we are unable to use blinding due to the treatment being a physically apparent intervention and the control being no intervention (which is our standard of care currently). The study team would ensure that infants allocated to the treatment group would receive the treatment starting between 8-21 days of age and once the infant has received at least one feed of 80 mL/kg/day, depending on the infant's skin maturity, as determined by the study team and in conjunction with the treating medical team. Infants who are intubated in the first week of life would qualify if they can be safely extubated within 2-3 weeks of life. Band placement would be started when they are extubated and on non-invasive support.
Device The device used in the treatment arm of this study will be the DandleLION NeoBellyBand. The NeoBellyBand is a Class 1 exempt abdominal binder which is included in DandleLION's Quality System and FDA registration. It is listed as a Medical Therapeutic Binder under product group MDR on Tarry Medical Products FDA establishment listing and does not require 510K clearance. (See: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm?lid=872457\&lpcd=MDR) Per the manufacturer, it is made of a medical-grade blend of fabric and foam that has been used safely on premature skin and has a soft foam inlay that is lightweight, breathable and moisture-wicking.
Treatment Protocol The band is intended to be in place at all times outside of cares times, skin-to-skin kangaroo care with the family, baths, and any procedures involving the abdomen. Once the bands have been placed on, they will stay in place while the infant is on non-invasive or invasive pressure support (CPAP, NIMV, or MV) and will be weaned off once the patient has been stable on high flow nasal cannula (HFNC) for two days. This means that for patients who have been exposed to non-invasive pressure ventilation and require re-intubation, the bands will also be worn during the time they remain re-intubated. The weaning will include three days of a schedule of 6 hour stretches with the band on and 6 hour stretches without the bands. If the patient requires pressure support again after the bands have been weaned off, the bands will be placed back on until they're weaned off pressure support again and weaned in the same way as above.
Control Protocol Infants will receive the standard of care for the NICU, except for additional data collection, which will include data on feeding interruptions and abdominal circumference measurements.
Data Collection from Chart The information that will be collected from the medical chart is information that is currently collected for patient care. The exceptions to this are the paper chart that tracks feeding disruptions and the nursing flow-sheet that tracks the times that the band is on or off, comments for when the band is off, and the abdominal circumference weekly. Data collected will include demographic information such as name, MRN, date of birth, sex, race and ethnicity, gestational age at birth and birth weight. It will include process measures, such as length of time the bands remained on the infant, documentation of abdominal circumference, abdominal circumference to head circumference measurement ratios, number of radiographs obtained for feeding intolerance, and glycerin use. It will include outcome measures, such as number of feeding interruption days, time to goal enteral feeds, time to all oral feeds, rates of chronic lung disease, necrotizing enterocolitis, spontaneous intestinal perforations, hernias and rates of incarcerated hernias, length of stay, and post-menstrual age at discharge.
Data Protection The study team members will collect retrospective data from their medical records securely, either while at the hospital, or through the secure Citrix system. The data will then be stored in a secure database, the RedCap database, for further analysis. The data contained within the RedCap database will be password-protected. Although the data collected will include protected health information and identifiable health information, all data will be de-identified prior to publication. Once the research study has been published, all identifiable data will be destroyed. De-identified data will be preserved as many journals now require a data availability statement.
Data Analysis For the primary outcome, the mean, standard deviation, standard error of the mean, and 95% confidence intervals will be calculated. The means will be compared between the cases and controls using a two-tailed t-test. If the primary outcome is noted to have a non-normal distribution, medians and interquartile ranges will be calculated and non-parametric Mann Whitney analyses will be conducted. For infants who do not withdraw from the study, an intent-to-treat analysis will be conducted. For secondary outcomes which have a continuous variable, the same statistical analyses will be used as the primary outcome. For secondary outcomes with a categorical variable, we will use proportions as well as chi-square tests. The statistical analyses will be conducted on the SPSS software and reviewed by a statistician.
Risk Monitoring Although we anticipate minimal risk to infants based on prior published data available about the NeoBellyBand, we will be tracking adverse events weekly. Rates of adverse events between the treatment and control arm will be analyzed after enrollment of the first 25 infants and will include documented pressure injuries and over-heating requiring removal of the band for \>6 hours. Although we do not anticipate any internal abdominal pathology to be a result of the placement of the bands, we will also be tracking rates of necrotizing enterocolitis, intestinal perforation, surgical abdomen, and incarcerated or strangulated hernias. Once the initial 25 patients have been enrolled (ideally about 11-14 from control group and treatment group), we will not start research interventions for new patients. We would continue to recruit more patients but will not carry out the research intervention until safety monitoring has been completed. The risk monitoring data will be reviewed by the research team, but also independently reviewed by a non-conflicted neonatologist at an outside institution.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Feeding Intolerance
Abdominal Distension
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
This is a randomized controlled trial of hospitalized preterm neonates born less than 32 weeks and 0 days gestational age (GA) on non-invasive respiratory support to evaluate respiratory and enteral nutrition outcomes of infants using abdominal binders compared with infants who are not using them.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Arm with Placement of NeoBellyBand (Abdominal Binder)
Treatment Arm with Placement of NeoBellyBand (Abdominal Binder): Trained personnel measure the infant's abdominal circumference and place a band that is to be worn for most of the day when the infant is on pressurized breathing support, such as CPAP or NIMV.
Group Type
EXPERIMENTAL
An abdominal binder
Intervention Type
DEVICE
This study involves the placement of an abdominal binder for preterm infants on non-invasive pressure breathing support.
Control Arm Receiving Standard of Care
Control Arm Receiving Standard of Care: The control arm will receive the standard of care in the NICU with the exception of additional study measures being collected such as weekly abdominal circumference measurements and data on feeding interruptions.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
An abdominal binder
This study involves the placement of an abdominal binder for preterm infants on non-invasive pressure breathing support.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Born at \<32w0d GA
* Chronologic age \>7 days, treatment or control protocol started by 21 days of life
* On non-invasive positive pressure respiratory support (NIMV or CPAP), either as primary support or after extubation from invasive mechanical ventilation
* Has received 80 mL/kg/day of feeds at least once
* Chronologic age \>7 days, treatment or control protocol started by 21 days of life
* On non-invasive positive pressure respiratory support (NIMV or CPAP), either as primary support or after extubation from invasive mechanical ventilation
* Has received 80 mL/kg/day of feeds at least once
Exclusion Criteria
* Skin integrity concerns
* Known abdominal or respiratory anomalies
* Umbilical lines in place
* Transferred to AMC NICU after 7 days of life
* Known genetic or major anatomic anomalies
* Known abdominal or respiratory anomalies
* Umbilical lines in place
* Transferred to AMC NICU after 7 days of life
* Known genetic or major anatomic anomalies
Maximum Eligible Age
1 Year
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Albany Medical College
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anshu Paul
Assistant Professor Of Pediatrics
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anshu Paul, MD
Role: PRINCIPAL_INVESTIGATOR
Albany Med Health System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Albany Med Health System
Albany, New York, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
McGill VE. Neonatal abdominal support to address CPAP belly: Two cases report and literature review. J Neonatal Perinatal Med. 2022;15(4):831-836. doi: 10.3233/NPM-221047.
Reference Type
BACKGROUND
Seiiedi-Biarag L, Mirghafourvand M. The effect of massage on feeding intolerance in preterm infants: a systematic review and meta-analysis study. Ital J Pediatr. 2020 Apr 23;46(1):52. doi: 10.1186/s13052-020-0818-4.
Reference Type
BACKGROUND
Ortigoza EB. Feeding intolerance. Early Hum Dev. 2022 Aug;171:105601. doi: 10.1016/j.earlhumdev.2022.105601. Epub 2022 Jun 10. No abstract available.
Reference Type
BACKGROUND
Gu H, Seekins J, Ritter V, Halamek LP, Wall JK, Fuerch JH. Characterizing continuous positive airway pressure (CPAP) Belly Syndrome in preterm infants in the neonatal intensive care unit (NICU). J Perinatol. 2024 Sep;44(9):1269-1275. doi: 10.1038/s41372-024-01918-2. Epub 2024 Mar 6.
Reference Type
BACKGROUND
Gounaris A, Costalos C, Varchalama L, Kokori P, Kolovou E, Alexiou N. Gastric emptying in very-low-birth-weight infants treated with nasal continuous positive airway pressure. J Pediatr. 2004 Oct;145(4):508-10. doi: 10.1016/j.jpeds.2004.06.030.
Reference Type
BACKGROUND
Jaile JC, Levin T, Wung JT, Abramson SJ, Ruzal-Shapiro C, Berdon WE. Benign gaseous distension of the bowel in premature infants treated with nasal continuous airway pressure: a study of contributing factors. AJR Am J Roentgenol. 1992 Jan;158(1):125-7. doi: 10.2214/ajr.158.1.1727337.
Reference Type
BACKGROUND
Shukla VV, Ambalavanan N. Recent Advances in Bronchopulmonary Dysplasia. Indian J Pediatr. 2021 Jul;88(7):690-695. doi: 10.1007/s12098-021-03766-w. Epub 2021 May 20.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7227
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study on the Effects of Feeding and Feeding Methods on Breathing Pattern in Very Low Birth Weight Preterm Infants
NCT00607555
COMPLETED
Pulmonary Volume Changes During Synchonized Noninvasive Positive Pressure Ventilation
NCT07237139
RECRUITING
Noninvasive NAVA Versus NIPPV in Low Birthweight Premature Infants
NCT03137225
TERMINATED
NA
Delayed Cord Clamping With Oxygen In Extremely Low Gestation Infants
NCT04413097
ACTIVE_NOT_RECRUITING
NA
To Determine the Best Feeding Practice in Preterm Infants on Non-invasive Ventilation.
NCT05824377
UNKNOWN
NA
Use of Gentle Synchronized Negative Pressure in Helping Babies Breathe
NCT03510169
UNKNOWN
NA
Comparing Different Delivery Systems of Continuous Positive Airway Pressure in Neonates
NCT06038565
WITHDRAWN
NA
Physiologically Based Cord Clamping To Improve Neonatal Outcomes In Moderate And Late Preterm Newborns
NCT06280872
RECRUITING
NA
Non-invasive Support in Extremely Preterm Infants
NCT02723123
UNKNOWN
NA
Respiratory Dynamics During Birth Stabilization in Preterm Infants Less Than 32+6/7 Weeks Gestation
NCT02748720
COMPLETED
NA
NIV-NAVA Versus Nasal Continuous Positive Airway Pressure (nCPAP) or Non Synchronized NIPPV
NCT02860325
COMPLETED
NA
Late Permissive Hypercapnia for Intubated and Ventilated Preterm Infants
NCT02799875
COMPLETED
NA
Sustained Lung Inflation and Pulmonary Mechanics in Preterm Infant
NCT02493920
WITHDRAWN
NA
"Effectiveness of Delivery Room Bubble CPAP in Preterm Infants With Respiratory Distress
NCT07162285
ENROLLING_BY_INVITATION
NA
Prematurity-Related Ventilatory Control
NCT03464396
COMPLETED
Sustained Lung Inflation in Preterm Infants
NCT03518762
COMPLETED
NA
Work of Breathing Description in Neonates With Congenital Diaphragmatic Hernia in NAVA and in Conventional Ventilation.
NCT03250793
COMPLETED
NA
Feasibility and Impact of Volume Targeted Ventilation in the Delivery Room
NCT03938532
TERMINATED
NA
Labor Status Monitor for Diagnosing True vs False Labor in Preterm Patients
NCT06157203
RECRUITING
Comparing Bubble and Ventilator Nasal CPAP in Preterm Infants
NCT02003846
COMPLETED
Comparison of Primary Extubation Failure Between NIPPV and NI-NAVA
NCT03242057
COMPLETED
NA
Impact of Delayed Cord Clamping and Minimally Invasive Surfactant Administration on Outcomes in Premature Infants Less Than 30 Weeks Gestation
NCT07092319
NOT_YET_RECRUITING
Impact of Currently Recommended Postnatal Nutrition on Neonatal Body Composition
NCT02622373
COMPLETED
Non-Invasive Neurally Adjusted Ventilatory Assist (NAVA) Prone vs Supine in Premature Infants
NCT05968586
COMPLETED
NA
Use of Dynamic Elastometric Body in Preterm Newborns
NCT05835765
ENROLLING_BY_INVITATION
NA